Clinical trials

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Precision medicine #Preclinical #RNA #Therapeutics #Translational #Translational chemistry

Cancer vaccine shows promising signs

The Translational Research Institute-based Mater researchers in partnership with The University of Queensland have developed a new cancer vaccine, which has shown promising signs in preclinical laboratory studies. Funded by grants from the Worldwide Cancer Research in the United Kingdom, and Mater Foundation, the new vaccine could be potentially… Read More

#Covid-19 #News

#Cell therapy #Clinical specialities #Clinical trials #Drug development #Immunology #Microbiology #Preclinical #RNA #Stem cells #System biology

Researchers find promising therapy to fight epidemic of liver disease

9 July 2020 Image: Science in HD So far there are no approved drugs for Non-Alcoholic Fatty Liver Disease In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising… Read More

#News

#AI / data analytics / healthtech / informatics #Biochemistry #Cell culture #Clinical specialities #Clinical trials #Drug development #Drug discovery #High Content Screening #Regulatory #RNA #Therapeutics

Cost-effective drug discovery: How this AI system aims to assist

Aigenpulse has released an intelligence platform designed to speed up the drug discovery and development process. The Aigenpulse platform harnesses the latest artificial intelligence (AI) and machine learning tools to deliver advanced analytics to underpin scientific decision making. Aigenpulse has built the data-agnostic platform for importing, integrating, processing, linking,… Read More

#Covid-19 #News

#Academic #Biomarkers #Business #Cell therapy #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Oncology #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Panthera and Rutherford Health launch oncology clinical trial network

7 July 2020 Rutherford’s independent network currently consists of four cancer treatment centres in Newport, Reading, Bedlington and Liverpool. It will draw patients from all over the UK offering pharma and CROs access to patients through more than 170 referring oncologists. Each of the Rutherford Cancer Centres has… Read More

#News

#Clinical specialities #Clinical trials #Drug discovery #Imaging

4D pharma enrolment for phase II study of MRx-4DP0004 for COVID-19 patients

4D pharma has announced that its phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients hospitalised with COVID-19 is now open to enrolment. Dosing of the first patients is expected shortly. The phase II randomised, double-blind, placebo-controlled trial is enrolling up to 90 patients admitted to hospital… Read More

#Covid-19 #News

#Analysis #Clinical specialities #Clinical trials #Drug discovery #Imaging

Sanofi and Regeneron stop Kevzara COVID-19 trial in US

Sanofi and Regeneron Pharmaceuticals have announced that the US Phase III trial of rheumatoid arthritis drug Kevzara (sarilumab) in COVID-19 patients requiring mechanical ventilation did not meet its main goals. Minor positive trends were observed in the primary pre-specified analysis group (critical patients on Kevzara 400mg who were… Read More

#Covid-19 #News

#Clinical specialities #Clinical trials #Drug discovery #Imaging #Lead discovery #Regulatory

Abivax treats first patient in COVID-19 clinical trial in France

The first patient has been treated in Abivax’s Phase IIa/III study of ABX464 in COVID-19 patients at the University Hospital Centre in Nice, France. The randomised, double-blind, placebo-controlled miR-AGE study investigates the effect of early treatment (at point of diagnosis) in 1,034 COVID-19 elderly or high-risk patients. The… Read More

#Covid-19 #News

#Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug discovery #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Oncology #Screening #Therapeutics

DDW summer issue now out

2 July 2020 From the race to the COVID-19 cure to the new manufacturing technologies that could be a game changer for stem cell therapies. With COVID-19 still a significant feature in the drug discovery landscape, this issue looks at the race to finding a cure – from… Read More

#News

#Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug discovery #High throughput screening #Imaging #Target validation

EUSA Pharma receives FDA approval of phase III clinical trial for siltuximab

2 July 2020 Image: Nino Liverani The US Food & Drug Administration (FDA) has approved a randomised, double-blind, placebo-controlled phase III clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab. It will also evaluate the standard of care in hospitalised patients with COVID-19 associated Acute… Read More

#News

#Biologics / Biotechnology #Cell therapy #Clinical specialities #Clinical trials #Drug discovery #Gene therapy #Imaging #Lead discovery #Precision medicine #RNA

Clinical trial examines alpha-1-antitrypsin for severe COVID-19 infection

Clinician scientists at RCSI University of Medicine and Health Sciences, Ireland, have begun a clinical trial of a promising therapy for critically ill COVID-19 patients in intensive care. In a paper published in the American Journal of Respiratory and Critical Care Medicine, the team, led by RCSI Professors… Read More

#Covid-19 #News

#Business #Clinical trials #Drug development #Drug discovery #Immunology / Virology & Vaccines #RNA

Symbiosis secures £1 million of growth finance from Allied Irish Bank

1 July 2020 Image: Micheile Henderson Symbiosis Pharmaceutical Services has secured £1million of finance from Allied Irish Bank (GB) to support its 2020 growth strategy. Symbiosis provides niche, sterile manufacturing services to global biotechnology and pharmaceutical company clients that are developing novel drug therapies and vaccines for use… Read More

#News

#Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Lead discovery #Oncology #RNA #Therapeutics #Translational #Translational chemistry

Major boost for AMR Centre as it receives share of Strength in Places Fund award

29 June 2020 Image: Mark Fletcher-Brown The AMR Centre has combined forces to attract investment to combat the global threat of antimicrobial resistance (AMR) resulting in a successful bid for a £114 million project supported by UK Research and Innovation (UKRI) The funding was secured by a North… Read More

#News

#Academic #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Lead discovery #RNA #Target validation #Therapeutics

Liverpool scoops £18.6 million research grant to tackle infectious diseases

26 June 2020 Image: Conor Samuel A Liverpool School of Tropical Medicine-led consortium has received an £18.6 million grant from the UK Research and Innovation (UKRI) Strength in Places Fund (SIPF) to deliver a major project to tackle infectious diseases, including COVID-19. The funding award recognises Liverpool City… Read More

#News

#Clinical trials #Drug discovery #High Content Screening #High throughput screening #Imaging #Lead discovery #Stem cells #System biology

Imaging system produces human cellular morphological data for COVID-19 research

With the COVID-19 pandemic impacting millions around the globe, researchers are racing to develop a vaccine or drug treatment. In an effort to better understand the cellular responses to COVID-19, the digital biology company Recursion has publicly released the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 approved… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Precision medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

PrecisionLife identifies 68 genes associated with risk of severe COVID-19

Scientists from AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. Prior to an effective… Read More

#Covid-19 #News